Lars Nieba

Chief Executive Officer at Engimmune Therapeutics AG

Net worth: 1 504 $ as of 2024-04-29

56 year

100 connections

Consumer Services

Health Technology

Finance

Profile

Lars Nieba is currently the Chief Executive Officer at Engimmune Therapeutics AG.
Previously, he worked as the Vice President at Bayer AG from 2016 to 2019.
He also served as the Chief Executive & Technology Officer at Nordic Nanovector ASA from 2020 to 2021.
Dr. Nieba was a Venture Partner at Pureos Partners AG from 2021 to 2023.
In terms of education, he holds a doctorate from the Max Planck Institute of Biochemistry, a graduate degree from the University of Freiburg (conferred in 1993), an MBA from the University of St. Gallen (conferred in 2003), and another doctorate from the University of Zurich (conferred in 1997).

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
THOR MEDICAL ASA 0.01%	2022-12-30	15,713 ( 0.01% )	1 504 $	2024-04-29

Lars Nieba active positions

Companies	Position	Start
Engimmune Therapeutics AG Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023.	Chief Executive Officer	2023-04-18

All active positions of Lars Nieba

Former positions of Lars Nieba

Companies	Position	End
Pureos Partners AG Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.	Private Equity Investor	2023-04-29
BAYER AG	Corporate Officer/Principal	2019-10-31
THOR MEDICAL	Chief Executive Officer	2021-04-05

See the detail of Lars Nieba's experience

Training of Lars Nieba

University of Freiburg	Graduate Degree
University of St. Gallen	Masters Business Admin
University of Zurich	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Lars Nieba's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BAYER AG	Health Technology

Private companies	3
Nordic Nanovector ASA Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.	Health Technology
Pureos Partners AG Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.	Finance
Engimmune Therapeutics AG Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023.	Technology Services

See company connections